I. AMENDMENTS TO THE CLAIMS

Claims 1 to 10. (Canceled)

Claim 11. (Currently Amended) Compounds or their salts having the following general formula (I):

~~$A\text{-}B_{b0}\text{-}C\text{-}N(O)_s$ (I)~~

$A\text{-}B\text{-}C\text{-}NO_2$ (I)

wherein:

~~$s = 2$~~

~~$b0 = 1$~~

A = $R\text{-}T_1$-, wherein:

R is the radical of a drug having formula $R\text{-}T_1\text{-}Z$ or $R\text{-}T_1\text{-}OZ$, wherein

T_1 = (CO) or X wherein:

X = O, S, N, NR_{1C} wherein:

R_{1C} is H or a linear or branched C_1-C_5 alkyl, or a free valence,

Z is H or a linear or branched C_1-C_{10} alkyl, selected from the group of anti-inflammatory drugs consisting of acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin, zomepirac, and tomoxiprol;

B = $-T_B\text{-}X_2\text{-}T_{B1}-$ wherein:

T_B and T_{B1} are equal or different, and

T_B = (CO) when T_1 is X,

T_B = X when T_1 is (CO), X being as above defined;

T_{B1} = (CO) or X, X being as above defined

X_2 is a bivalent bridging group such as the corresponding precursor of B, having the formula $-T_B\text{-}X_2\text{-}T_{B1}-$ in which the T_B and T_{B1} free valence are saturated with OH or

H, is selected from the group consisting of the amino acids aspartic acid (PI), histidine (PII), 5-hydroxytryptophan (PIII), 4-thiazolidincarboxylic acid (PIV), and 2-oxo-4-thiazolidincarboxylic acid (PV):



(PI)



(PII)



(PIII)



(PIV)



(PV)

C is the bivalent radical $-T_C-Y-$ wherein:

T_C = (CO) when T_{B1} is X, or

T_C = X when T_{B1} is (CO), X being as above defined,

Y is Y_0 = an alkylenoxy group R'O wherein

R' is linear ~~or, when possible, branched~~ or branched C_1 to C_{20} alkyl.

Claim 12. (Canceled)

Claim 13. (Currently Amended) A method for the treatment of pathologies associated with stress oxidative and/or endothelial dysfunction comprising administering compounds or salts ~~Use of compounds or salts~~ according to claim 11 ~~for the preparation of drugs for the treatment of pathologies associated with stress oxidative and/or endothelial dysfunction~~.

Claim 14. (Previously Presented) Pharmaceutical formulations containing as active principle the compounds or salts thereof of claim 11.